• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

术前接种新型冠状病毒疫苗与患者术后谵妄的关系

Relationship between preoperative SARS-CoV-2 vaccination and postoperative delirium

摘要目的:评价术前接种新型冠状病毒疫苗与患者术后谵妄(POD)的关系。方法:选择2020年6月至2022年6月择期在腰硬联合麻醉下行膝/髋关节置换术患者938例,性别不限,年龄50~90岁,体质量50~90 kg,ASA分级Ⅰ或Ⅱ级,术前简易智力状态检查量表评分≥24分,无沟通障碍。记录术前6个月内新型冠状病毒灭活疫苗接种情况。腰麻穿刺针成功进入蛛网膜下腔后抽取2 ml脑脊液,采用ELISA法测定β淀粉样蛋白42(Aβ42)、总tau蛋白(t-tau)和磷酸化tau蛋白(p-tau)浓度,计算Aβ42/t-tau比值和Aβ42/p-tau比值。术后7 d内或出院前,每天2次采用意识错乱评估量表评估POD发生情况。根据患者是否发生POD分为POD组和非POD组。将具有重要临床意义的POD影响因素及单因素回归分析中 P<0.20的因素纳入多因素logistic回归分析,研究术前接种新型冠状病毒疫苗和脑脊液生物标志物水平与POD的关系。 结果:最终纳入875例患者,其中169例患者发生了POD,发生率为19.3%。logistic回归结果显示,术前6个月内接种新型冠状病毒灭活疫苗、术前脑脊液Aβ42浓度、Aβ42/t-tau比值和Aβ42/p-tau比值升高是POD的保护因素,术前脑脊液t-tau浓度和p-tau浓度升高是POD的危险因素( P<0.05)。在加入性别、年龄、术前MMSE评分、受教育年限、饮酒史、合并高血压、糖尿病和冠心病调整混杂因素后,结果仍表明术前6个月内接种新型冠状病毒灭活疫苗是患者POD的保护因素( P<0.05)。 结论:术前6个月内接种新型冠状病毒灭活疫苗是患者POD的保护因素。

更多

abstractsObjective:To evaluate the relationship between preoperative SARS-CoV-2 vaccination and postoperative delirium(POD) in the patients.Methods:A total of 938 participants of either sex, aged 50-90 yr, weighing 50-90 kg, of American Society of Anesthesiologists Physical Status classificationⅠorⅡ, with preoperative Mini-Mental State Examination score ≥24, without communication barriers, undergoing elective knee or hip joint replacement under combined spinal-epidural anesthesia from June 2020 to June 2022 in Qingdao Municipal Hospital, were enrolled. The vaccination with SARS-CoV-2 inactivated vaccine within 6 months before operation was recorded. The cerebrospinal fluid 2 ml was extracted after the puncture needle was successfully inserted into the subarachnoid space for determination of the concentrations of Aβ42, total tau protein (t-tau), and phosphorylated tau protein (p-tau) by enzyme-linked immunosorbent assay (by enzyme-linked immunosorbent assay). The Aβ42/t-tau and Aβ42/p-tau ratios were calculated. POD was assessed using the Confusion Assessment Method twice a day within 7 days after surgery or before discharge.The patients were divided into POD group and non-POD group according to whether they developed POD. The risk factors of which P values were less than 0.20 in the univariate logistic regression would enter the multivariate logistic regression analysis to investigate the relationship between SARS-CoV-2 vaccine and level of cerebral spinal fluid (CSF) biomarkers and POD. Results:Eight hundred and seventy-four patients were finally enrolled in the analysis, of which 169 patients developed POD, with an incidence of 19.3%.The results of logistic regression showed that vaccination with SARS-CoV-2 inactivated vaccine within 6 months before operation, preoperative concentrations of Aβ42 in CSF, and increase in Aβ42/t-tau and Aβ42/p-tau ratios were protective factors for POD, and preoperative elevated concentrations of t-tau and p-tau in CSF were risk factors for POD ( P<0.05). After gender, age, preoperative Mini-Mental State Examination score, years of education, history of drinking, hypertension, diabetes mellitus and coronary heart disease were added to eliminate the influence of confounding factors, the results still showed that vaccination with SARS-CoV-2 inactivated vaccine within 6 months before operation was a protective factor for POD. Conclusions:Vaccination with SARS-CoV-2 inactivated vaccine within 6 months before operation is a protective factor for POD in patients.

More
广告
作者 张浩然 [1] 陈奕涵 [2] 林旭 [2] 王彬 [2] 杨云超 [3] 毕燕琳 [2] 学术成果认领
作者单位 潍坊医学院麻醉学院,潍坊 261053 [1] 康复大学青岛医院(青岛市市立医院)东院区麻醉科,青岛 266071 [2] 青岛大学第三附属医院麻醉科,青岛 266071 [3]
栏目名称 围术期并发症
DOI 10.3760/cma.j.cn131073.20230116.00503
发布时间 2025-02-25
基金项目
国家自然科学基金 National Natural Science Foundation of China
  • 浏览39
  • 下载1
中华麻醉学杂志

中华麻醉学杂志

2023年43卷5期

526-530页

ISTICPKUCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷